Praxis Precision Medicines Inc - Asset Resilience Ratio
Praxis Precision Medicines Inc (PRAX) has an Asset Resilience Ratio of 17.16% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Praxis Precision Medicines Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Praxis Precision Medicines Inc's Asset Resilience Ratio has changed over time. See what is Praxis Precision Medicines Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Praxis Precision Medicines Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRAX stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $250.53 Million | 17.16% |
| Total Liquid Assets | $250.53 Million | 17.16% |
Asset Resilience Insights
- Good Liquidity Position: Praxis Precision Medicines Inc maintains a healthy 17.16% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Praxis Precision Medicines Inc Industry Peers by Asset Resilience Ratio
Compare Praxis Precision Medicines Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Praxis Precision Medicines Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Praxis Precision Medicines Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.80% | $242.00 Million | $937.91 Million | -10.88pp |
| 2024-12-31 | 36.68% | $177.19 Million | $483.11 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $87.95 Million | -- |
| 2022-12-31 | 33.77% | $38.87 Million | $115.13 Million | -13.10pp |
| 2021-12-31 | 46.87% | $137.21 Million | $292.75 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $303.18 Million | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more